Daré Bioscience (NASDAQ:DARE – Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.02, Zacks reports. The business had revenue of ($0.06) million for the quarter, compared to analysts’ expectations of $1.00 million.
Daré Bioscience Price Performance
NASDAQ:DARE opened at $2.92 on Tuesday. The company’s fifty day moving average price is $3.06 and its 200-day moving average price is $3.29. Daré Bioscience has a 1-year low of $2.67 and a 1-year high of $7.56. The firm has a market capitalization of $25.40 million, a P/E ratio of -4.92 and a beta of 1.38.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a report on Tuesday.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
See Also
- Five stocks we like better than Daré Bioscience
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Berkshire Hathaway Gains Defy Stock Market Slump
- Following Congress Stock Trades
- Palantir Stock Builds Momentum on New Partnership
- Why Invest in High-Yield Dividend Stocks?
- Tech Sell-Off Makes Microsoft Stock Look Like a Steal
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
